OurCrowd

Founded in 2013 by Jon Medved in Jerusalem, OurCrowd has grown into one of the largest equity crowdfunding and venture investing platforms in the world, channeling accredited capital into Israeli and global startups across healthtech, medtech, enterprise software, and frontier technologies. The platform sits at the intersection of traditional venture capital and member-driven investing, giving founders access to a global investor base that exceeds many traditional funds in scale.

OurCrowd’s healthcare thesis spans digital health, AI/ML in healthcare, and medical devices. The firm participates in rounds where Israeli engineering talent and clinical research collide, often syndicating alongside top-tier institutional VCs. Its portfolio reflects a willingness to back both software-led care delivery and capital-intensive medical hardware, with deep ties into the Israeli innovation ecosystem and the global hospital systems that pilot its companies’ technologies.

Checks typically range from $1M to $5M, deployed across Seed through Series C. Geographically, the platform is anchored in Jerusalem but operates globally, with investor bases concentrated in North America, Europe, the Gulf, and Asia. This international reach makes OurCrowd unusually well-positioned to help founders open distribution channels and find strategic partners outside their home market, particularly for companies with regulatory or commercial ambitions in multiple jurisdictions.

The team blends institutional venture experience with operational backgrounds in technology, finance, and healthcare. Decisions move through a centralized investment committee that vets opportunities for both portfolio fit and platform-investor appetite, meaning founders benefit from a structured diligence process rather than the variable feedback common to syndicates.

OurCrowd’s approach to founders emphasizes capital efficiency and follow-on support. The platform leans into companies where Israel’s particular strengths in computer vision, signal processing, and clinical-trial design create defensible technical moats. Founders who fit best are typically those with a working product, early clinical or commercial validation, and a path to international scale that benefits from a globally distributed cap table. Inbound interest is welcomed, though warm introductions through portfolio founders or syndicate partners tend to surface most effectively. Reporting expectations are professional and quarterly, in line with traditional institutional VC norms, and OurCrowd actively supports portfolio companies with follow-on rounds, business-development introductions across its network, and access to its annual Global Investor Summit, which has become one of the larger gatherings of innovation capital in the region. For healthcare founders specifically, the firm’s medtech and digital health relationships across academic medical centers and integrated delivery networks help accelerate pilots and reference customers, which is often the difference between a Series A pitch that converts and one that stalls.